Acetildenafil Stats & Data

Acetildenafil is an unapproved sildenafil‑like PDE‑5 inhibitor repeatedly detected as an undeclared adulterant in “herbal” sexual‑enhancement supplements; such products often contain variable and unlabeled amounts of PDE‑5 analogues, so potency is unpredictable. This substantially raises overdose risks (hypotension, syncope, severe headache) compared with regulated prescription PDE‑5 inhibitors. Seek products only from known, tested sources; routine reagent kits cannot detect PDE‑5 analogues—laboratory methods (HPLC/LC‑MS) are required. PDE‑5 inhibitors are absolutely contraindicated with nitrate/nitrite drugs or poppers; combining them can cause precipitous, life‑threatening blood‑pressure drops—do not take nitrates for at least 24 h after a dose. Avoid co‑use with riociguat or other sGC stimulators due to additive cGMP effects and severe hypotension. Strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat) can raise exposures dramatically; sildenafil AUC increases ~11‑fold with ritonavir—similar class effects are plausible here; avoid unless a clinician specifically advises. Sudden vision loss, visual color tinge, or hearing changes require urgent evaluation; rare cases of NAION and ototoxicity are associated with PDE‑5 inhibitors, especially in older males or those with vascular risk factors. Priapism (erection >4 h) is a medical emergency; seek urgent care to prevent permanent injury. Use caution with alpha‑blockers and other antihypertensives; start low and monitor for dizziness/syncope. High‑fat meals delay sildenafil absorption and reduce Cmax; acetildenafil likely behaves similarly by class analogy—consider timing relative to food for predictable onset. People with significant cardiovascular disease, recent MI/stroke, severe hypotension, multiple system atrophy, or inherited retinal disorders should avoid PDE‑5 inhibitors or use only under medical supervision. Limit to once per 24 h; daily or frequent re‑dosing increases adverse‑event risk without clear benefit. Because this compound lacks formal human PK/PD data, conservative dosing and slow titration are essential.